Sophia Lopez supports clients with research and analysis that spans a variety of healthcare sectors and stakeholders.
She applies her clinical and public health policy backgrounds to a broad range of client projects.
Before joining Avalere, Sophia held a variety of positions, including a graduate research position at the USC Institute of Inequalities in Global Health, where she performed research on global policies related to the Sustainable Development Goals. Additionally, she worked at the Developmental Therapeutics branch of the National Institutes of Health, supporting lung cancer research.
Sophia has an MPH and a BS in global health from the University of Southern California.
Authored Content
At IDWeek, Avalere Health connected with industry and academic leaders on the evolving vaccine policy, access, value, and evidence landscape.
Over time, the percentage of generic prescription drugs placed on Medicare Part D generic tiers has declined, from 65% in 2016 to 43% in 2025.
As the processes, priorities, and membership within the ACIP evolve, vaccine manufacturers should adapt their evidence generation planning to support optimal review.
Avalere identified 19 states that must change their Medicaid vaccine policies to comply with the IRA’s requirement that states cover all recommended vaccines without cost sharing.
New Avalere analysis examines longitudinal trends across a cohort of generic drugs, finding increases in aggregate patient spending over time and in placement on higher tiers in Medicare Part D.
An Avalere analysis finds that, in 2020, 63% of Medicare Part D beneficiaries paid the full cost of their generic medications at least once during their initial coverage phase when the generics were on the preferred brand tier.